skip to Main Content

SPEAKERS

SAMPLE OF KEYNOTE SPEAKERS AND THEIR CASE STUDIES

Eduardo Bittencourt de
GOMENSORO

Cluster Medical Affairs Director

CASE STUDY / DAY 1

Delivering the Next Generation of Medicines and Vaccines to Patients: The Digitally-Enhanced Role of MSLs

Scientific evidence emerges constantly in disease areas of interest to the pharmaceutical industry, and it is an increasing challenge for the medical community to rapidly digest and translate it into clinical practice to help the patients. To address this, the goal of medical affairs is to provide early and continuous scientific engagement with external experts (EEs) and investigators – from early-phase research through a product’s lifecycle – to establish trust, build scientific rapport and accelerate understanding of complex new medicines and vaccines.

  • Medical Science Liaisons’ (MSLs) main objective is to provide early and continuous scientific engagement with external experts (EEs) and investigators
  • There is an increasing challenge for the medical community to rapidly digest and translate scientific evidence into clinical practice to help the patients
  • To ensure MSLs are best positioned to deliver, new capabilities and tools in the digital field are becoming critical

CASE STUDY / DAY 1

How to Define the Right Level of Medical Affairs Activities

The value of MA could sometimes only be assessed accordingly to the stage of a product in its life-cycle – thus leading sometimes to a perception that MA activities could be restricted to the preparation/accompaniment of new launches. However, the value of MA should be put in the perspective with 1.) the diversity of country archetypes/needs, 2.) the level of new data or medical paradigm evolution in the related disease and 3.) the importance of the product for the company. Level of MA related activities should be adjusted based on:

  • The stage of the product in its lifecycle
  • The diversity of country’s needs (developed markets versus emerging markets)
  • The magnitude of new data/paradigm
  • The importance of the product for the company

Jacques
THEVENON

Head of International Medical Affairs

This year Summit will host speakers from the world’s leading companies.
See sample of key note speakers.

Gunnar
PHILIPP

Senior Director Medical Affairs

Jacques
THEVENON

Head of International Medical Affairs

Kwaku
MARFO

WorldWide Medical Affairs Director

Eduardo Bittencourt de
GOMENSORO

Cluster Medical Affairs Director

Carmen
MAZZOLA

Medical and Regulatory Affairs Director

Dr. Parveen
JAYIA

Medical Director, UK IRE, CEE

CASE STUDY / DAY 2

The Internet of Medical Things: Leveraging Technology to Drive Clinical Behaviour Change

Digital technologies and the Internet of Medical Things are becoming increasingly embedded in medical affairs strategy and tactics. How we leverage these tools to drive medical impact is centred on our ability to gather actionable insights to make emotional connections with what matters most to the patients and clinicians. During this presentation, we will highlight the “hands on” case study which is an immersive educational experience to promote clinical empowerment, earlier disease identification and diagnosis to improve patient outcomes.

Kwaku
MARFO

WorldWide Medical Affairs Director

Dr. Parveen
JAYIA

Medical Director, UK IRE, CEE

CASE STUDY / DAY 2

Medical Affairs Leading Strategic Partnerships: Building a Bolder Medical Affairs Vision

In the evolving technology and economic environment there is a need for medical affairs to take on a more strategic leadership role. The expertise housed within medical affairs departments needs to be capitalised upon to articulate not only the clinical but also the economic value a medicine can bring. Internal challenges and barriers seem to prevent the true value of medical affairs being realised and these skills utilised. We need to establish how we can increase the internal value proposition of the medical affairs department to enable medical affairs to lead strategic payer/clinician partnerships.

  • Transforming and personalising medical engagement – Understanding the real education need and collaborating
  • Life cycle management through generation of real world evidence and timely integration of generated data to optimise outcomes
  • Transformation of medical leadership, making key decisions and changing the external perceptions of pharmaceutical industry
FOR MORE INFORMATION REQUEST FULL PROGRAMME

See what keynote speakers will be taking part in the exclusive speaking panel.
Explore what Case Studies will be discussed by our senior corporate speakers

2nd Annual Global Medical Affairs Summit
TIME IS RUNNING OUT! DON’T RISK MISSING IT

THANK YOU FOR YOUR CALL REQUEST

You will be contacted shortly.

Back To Top

RELATED EVENT

7th Annual Pharma Customer Experience Management Summit
9th Annual Pharma Strategic Sourcing & Procurement Summit